Thursday, September 20, 2012, 12:33 PM
Stephens gives a boost to a couple medical instrument stocks today, initiating Synergetics (SURG +15.6%) and Uroplasty (UPI +5.6%) both with Overweight ratings (I, II). SURG designs microsurgical instruments primarily for ophthalmology and neurosurgery markets, while UPI is a medical device company that develops, manufactures and markets products for the treatment of voiding dysfunctions.
Comment![Healthcare, On the Move]
Friday, May 25, 2012, 10:27 AM
Uroplasty (UPI +9.6%) pops after its FQ4 results beat estimates on narrower losses. Global sales increased 39% Y/Y, while sales in the U.S. grew by 63%. The higher U.S. numbers were driven by a 79% increase in sales of its Urgent PC Neuromodulation System, and a 53% jump in sales of its Macroplastique. Separately, JMP Securities upgraded the shares to Outperform on the back of the better-than-anticipated report.
Comment![Healthcare, Earnings, On the Move]
Tuesday, May 22, 2012, 12:15 PM
Roth Capital takes advantage of a 66% price drop over the past year to upgrade Uroplasty (UPI -2.1%) to Buy on valuation. Roth says the company is well positioned for higher relative growth and has better margins versus its peers.